We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Protocol Rapidly Detects Three Legionella Species

By LabMedica International staff writers
Posted on 01 Mar 2016
An innovative protocol has been developed for the detection of the three most prevalent Legionella species, enabling the source of the infection to be located in just eight hours.

The genus Legionella is a pathogenic group of Gram-negative bacteria that includes the species L. More...
pneumophila, causing legionellosis and illnesses caused by Legionella include a pneumonia-type illness called Legionnaires' disease and a mild flu-like illness called Pontiac fever.

Scientists at the Polytechnic University of Valencia (UPV; Spain) initially based their investigation on a study carried out by a Japanese research group aiming to detect as many as four Legionella species simultaneously. However, the UPV team found that this approach was not viable and began devising a protocol for just three species: L. pneumophila (the bacteria responsible for 90% of human Legionella cases, L. micdadei and L. longbeachae. The protocol is considered a breakthrough that relies on the combined use of a multiplex polymerase chain reaction (Multiplex PCR) and pretreatment with propidium monoazide (PMA).

The new protocol brings detection time down from 14 days to just eight hours, which is a marked improvement on the most commonly used detection method. It can also be used successfully in very contaminated samples, where existing methods cannot. Yolanda Moreno Trigo, PhD, the senior scientist on the project, said, “We concentrated the sample, broke the bacteria in order to extract its DNA and then used Multiplex PCR to identify the different Legionella species. The Multiplex PCR amplifies the DNA of the target species, making it easier to identify them. Pretreatment with PMA allows us to immediately discard the DNA of the dead cells, which we are not interested in.”

Related Links:

Polytechnic University of Valencia 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.